You are here: Industry Insights > Market News > Bring it on, pharma: Finger-pointing at insurers provokes AHIP tweetstorm

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

rhSOD

Bring it on, pharma: Finger-pointing at insurers provokes AHIP tweetstorm

fiercepharmaSeptember 29, 2017

Tag: AHIP , insurers , Pharma

Favorites

Call it unintended-but-predictable consequences: Launched this summer, a pharma industry campaign called "Let's Talk About Cost" highlights the role of insurers and middlemen in drug spending. Now, top insurers are talking back, with no punches pulled.

America's Health Insurance Plans, the insurance industry's lobby group, called out pharma on Twitter in a series of posts about drug expenses, misuse of drug laws, price hikes, patent deals and more. It isn't the first time the industries have sparred and won't be the last.

Previous:Lilly steps up to rival Pfizer, Novartis with Verzenio breast cancer approval

Next:Iconic Landmarks Turn Red for World Heart Day: Friday 29 September 2017

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Gan & Lee Pharmaceuticals is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct a phase 2 clinical trial.

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Bring it on, pharma: Finger-pointing at insurers provokes AHIP tweetstorm | Pharmasources.com

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

Bring it on, pharma: Finger-pointing at insurers provokes AHIP tweetstorm

Related News

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

You may like
More>>

Bring it on, pharma: Finger-pointing at insurers provokes AHIP tweetstorm

Related News

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

You may likeMore>>

You may like
More>>